Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

Exclusion Criteria

• •AD subjects with exfoliative erythroderma or lacking a minimum 10 cm diameter area of normal appearing skin on the deltoid or thigh vaccination sites
• •Have a body mass index (BMI) of 30 or greater at the Screening Visit
• •Known history of infection with YFV, dengue fever, TBEV, JEV, or West Nile Virus (WNV)
• •A family history of severe reactions to the yellow fever vaccine
• •Traveled to Africa or South America (including participants who plan to travel to these areas prior to completion of the study)
• •History of egg allergy or have a positive egg allergy skin prick test that is administered at the Screening visit
• •History of acute hypersensitivity reaction to any components of the yellow fever vaccine (including gelatin)
• •Have latex allergy
• •Have lidocaine allergy
• •Are allergic or hypersensitive to TegadermTM
• •Received systemic immunosuppressants within 30 days prior to receiving the vaccination
• •Received systemic corticosteroids, anti inflammatory biologics (e.g., alefacept, etanercept, etc.), or calcineurin inhibitors within 30 days prior to receiving the vaccination
• •Received systemic antibiotics or antivirals within 7 days of receiving the vaccination
• •Received greater than 440 mcg of inhaled steroids per day within 6 months prior to receiving the vaccination
• •Received Xolair (Omalizumab) within 1 year prior to receiving the vaccination
• •Received immunotherapy within 30 days prior to receiving the vaccination
• •Received any vaccine within 30 days prior to randomization or expected receipt 30 days after randomization
• •Received topical antibiotics, antivirals, immune enhancers (e.g., imiquimod), or calcineurin inhibitors within 7 days prior to receiving the vaccination
• •Received topical corticosteroids within 7 days prior to receiving the vaccination
• •Received phototherapy (e.g., ultraviolet light B \[UVB\], psoralen plus ultraviolet light A \[PUVA\]) within 30 days prior to receiving the vaccination
• •Acute febrile illness or active fungal, bacterial, or viral infections (subjects may be reconsidered for enrollment once the condition has resolved)
• •Skin disease other than AD that might compromise the stratum corneum barrier (e.g., clinically evident ichthyosis, bullous disease, psoriasis)
• •Current or past history of malignancy or of autoimmune or immunodeficiency diseases. More information on this criterion can be found in the protocol.
• •Pregnant or breastfeeding
• •Have an anti-nuclear antibody (ANA) titer that is equal to or greater than 1/160 at the Screening Visit
• •Have a serum immunoglobulin (Ig)G, IgM, IgA, C3, or C4 level below the normal range at the Screening Visit
• •Have a manual lymphocyte count that is less than 1000 lymphocytes per microliter